La méningite est mortelle et débilitante ; elle frappe brutalement ; elle a de graves conséquences sanitaires, économiques et sociales et touche tous les âges de la vie dans tous les pays du monde. La méningite bactérienne peut être à l’origine d’épidémies, entraîner la mort dans les... 24 heures et un patient sur cinq peut rester handicapé à vie à la suite d’une infection. La plupart des cas et des décès dus à la méningite pourraient être évités par la vaccination mais les progrès obtenus pour la vaincre sont bien moins rapides que ceux réalisés contre d’autres maladies à prévention vaccinale.
more
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
Vaccines are supported by decades of medical research. ...They work by preparing the body's own immune system to recognise and defend against a specific disease. The volume of information available about vaccination can be overwhelming, so it’s important to talk through the topic.
Available in different languages
more
This article is part four in a series of explainers on vaccine development and distribution
Available in different languages
Many people have questions about the new coronavirus disease 2019 (COVID-19) vaccines. As vaccine recipients’ most-trusted source of information on vaccines, you play a critical role in helping them understand the importance of COVID-19 vaccination, as well as if and when it is likely to be recomm...ended for them.
The materials include proven communication strategies and tips for effectively setting expectations and addressing questions from COVID-19 vaccine recipients.
more
The Global Vaccine Action Plan (GVAP) 2011-2020, endorsed by Member States during the May 2012 World Health Assembly, has set ambitious targets to improve access to immunization and tackle vaccine-preventable diseases. This responsibility has been translated into firm commitments in February 2016, t...hrough the signature of the Addis Declaration on Immunization (ADI) by African Ministers and subsequently endorsed by the Heads of States from across Africa at the 28th African Union Summit held in January 2017. This commitment from the highest level of government comes as a catalyst to immunization efforts on the continent to deliver on the promise of universal immunization
more
Circulating vaccine-derived poliovirus type 2 in Angola
Ebola virus disease in Democratic Republic of the Congo
Dengue fever in Côte d’Ivoire
Humanitarian crisis in north-east Nigeria.
Find out how many vaccine doses have been given in your country using WHO’s COVID-19 dashboard
Rabies is a vaccine-preventable viral disease which occurs in more than 150 countries and territories. Dogs are the source of the vast majority of human rabies deaths, contributing up to 99% of all rabies transmissions to humans.
Rabies is a vaccine-preventable, zoonotic, viral disease affecting the central nervous system. Once clinical symptoms appear, rabies is virtually 100% fatal. In up to 99% of cases, domestic dogs are responsible for rabies virus transmission to humans. Yet, rabies can affect both domestic and wild an...imals. It spreads to people and animals via saliva, usually through bites, scratches or direct contact with mucosa (e.g. eyes, mouth or open wounds). Children between the age of 5 and 14 years are frequent victims.
more
Information about vaccine administration
WHO's 'Vaccine Explained' series features illustrated articles on vaccine development and distribution. Learn more about vaccines from the earliest of research stages to their rollout in countries.
Availble in different languages
Vaccinator's Manual SINOPHARM Vaccine - 28 FEBRUARY 2021
COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important
to identify sources of variation so that policies can be tailored to different population groups. ...In this paper, we analyze the results from a survey designed and implemented in order to identify early adopters and
laggers in six big cities of Latin America. We find that trust in government and science, accurate knowledge about the value of vaccination and vaccine effects, perceived risk of getting sick, and being a student
increase the odds to get vaccinated. We also identify potential laggers as women and populations between 20 and 35 years old who are not students. We discuss specific strategies to promote vaccination among
these populations groups as well as more general strategies designed to gain trust. These findings are specific to the context of Latin America insofar as the underlying factors associated with the choice to be
vaccinated vary significantly by location and in relation to individual-level factors.
more
This resource explains how WHO EUL COVID-19 vaccines without vaccine vial monitor or VVM should be handled at the vaccination site, to ensure that safe and potent vaccines are administered.
This document has been updated: 31 August 2021
Child and adolescent vaccine safety report
This report on the safety of COVID-19 vaccination in children and adolescents in Argentina includes data from the start of the adolescent campaign
in Argentina, includes data reported since the start of the campaign in adolescents (28 July 2021) and in ch...ildren aged 3-11 years (12 October 2021) until 6 AM on 31 October 2021.
more
Int J Vaccines Vaccin 2016, 2(1): 00018, January 29, 2016
WHO's 'Vaccine Explained' series features illustrated articles on vaccine development and distribution. Learn more about vaccines from the earliest of research stages to their rollout in countries.
The WHO Cholera Vaccine Position Paper (August 2017) highlights the importance of oral cholera vaccines (OCVs) as a key tool in outbreak response and prevention, alongside water, sanitation, and hygiene (WASH) measures. It recommends OCVs for high-risk populations, endemic areas, and humanitarian cr...ises, emphasizing their effectiveness in reducing cases and mortality. The paper discusses two types of OCVs (Dukoral®, Shanchol™, Euvichol®) and supports the WHO-managed vaccine stockpile for rapid deployment in cholera-prone regions.
more
WHO's 'Vaccine Explained' series features illustrated articles on vaccine development and distribution. Learn more about vaccines from the earliest of research stages to their rollout in countries.
Availble in different languages
Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE)